Step 1: Gather and Analyze Data, Part 2

Data collection (continued):

  • Local patient safety:  Clostridium difficile infection rate
    • Often routinely collected and publicly reported
    • Associated with both infection control practices AND antimicrobial use
    • Important to both clinical and administrative audiences, helps to establish a sense of urgency
    • Reference(s):
      • Valiquette L, et al. Clin Infect Dis 2007; 45:S112–21.
    • Local patient safety:  antibiotic resistance
      • Local susceptibility data (e.g. antibiogram) are invaluable for guiding empiric therapy, e.g. if E. coli susceptibility towards ciprofloxacin is low in an institution where its usage is relatively high, efforts can be directed at educating clinicians to avoid this agent as first line therapy for infections where E. coli is a common pathogen.  Meaningful changes in susceptibility data following changes in prescribing patterns may not occur in the short term (e.g. six months), so be patient.
      • References
        • Pakyz A. Pharmacotherapy 2007;27(9):1306-12
        • Kuper KM, et al. Pharmacotherapy 2009;29(11):1326-1343

    Armed with this type of information, you can develop a business case, which is needed to solicit formal support and endorsement for your ASP from leadership and key stakeholders at your facility.

    Useful links:

    Next:  Step 2:  Create the Guiding Coalition, Part 1